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 Prior to the 1990s, antipsychotic prescribing to children and adolescents was 
uncommon, given the scarcity of safety data and the high risk of developing extrapyramidal 
side effects.  The emergence of second generation antipsychotics, changes in the 
epidemiology of pediatric mental health disorders, and expansion of antipsychotic drug use 
have facilitated the uptake of pediatric prescribing.  The speed at which these drugs are 
being taken up by this vulnerable population is a concern.  From 2002 to 2008, 
antipsychotic use in pediatric patients increased by 65% from 2.9 million to 4.8 million 
prescriptions.1   Until 2006, all atypical antipsychotic prescribing was off-label, as these 
drugs were not approved by the FDA for use among children and adolescents.  Using 
national retail prescription data of children and adolescents ages 0-17 obtained from IMS 
Health covering the years 2005-2008, the effect of the 2006 and 2007 FDA approvals of 
Risperdal for specific pediatric use was examined using segmented interrupted time-series 
regressions.  The analysis reveals that the FDA approvals had a statistically significant 
level effect but no trend effect on Risperdal prescribing.  In addition, there was a stronger 
level effect observed among non-mental health specialists compared to psychiatrists and 
other mental health specialists.  The results of this study suggest that FDA pediatric 
approvals have an important role in legitimizing and facilitating prescribing, as there are 
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 Over the past two decades, the use of antipsychotic prescriptions has changed from 
treating adults with severe psychotic disorders to treating a wider range of disorders for a 
more diverse population. This change in prescribing has led to exponential increases in 
overall utilization and expenditure.  As a result, spending on antipsychotic prescriptions is 
roughly $13.1 billion annually, exceeded only by lipid regulators, proton pumps, and 
antidepressants.  Within the Medicaid program, antipsychotics have become the most costly 
drug class, accounting for more than 15% of overall drug spending. (Crystal, Olfson, Huang, 
Pincus, & Gerhard, 2009) Given these trends, it is becoming increasingly important to 
consider the appropriateness and possible consequences of antipsychotic prescribing to this 
new diverse population that now includes young children and adolescents.  It is also equally 
important to ask who is being prescribed these antipsychotics, by whom, and for what 
reasons. 
  
The origins of Antipsychotics 
 Antipsychotics (also referred to as neuroleptics) are a class of drugs used primarily to 
manage psychotic symptoms such as hallucinations, delusions, and disorganized thinking 
and behavior. (Ivanov & Charney, 2008) The first antipsychotic drug chlorpromazine 
(marketed under the name Thorazine) originated from Paul Erhlich’s early work 
researching the antimalarial effects of phenothiazine derivatives in the late 1800s.  First 
introduced in the late 1950s, the widespread use of chlorpromazine drastically reduced 




derivatives.  Between 1954 and 1975, 15 antipsychotic drugs were introduced in the United 
States.  These included haloperidol, thioridazine, thiothixene, loxapine, and trifluoperazine.  
Despite their clinical benefit, these first generation antipsychotics were observed to have 
relatively high risks of extrapyramidal symptoms (adverse neurological responses) that 
include parkinsonism, dystonias, akathisia, and tardive dyskensia.  (Shen, 1999)  Given the 
severity and intrusion of these side effects, these first generation antipsychotics were only 
prescribed to adults with severe psychotic disorders in cases where the benefits clearly 
outweighed the risk of extrapyramidal symptoms. 
 Beginning in the 1990s, a new drug, clozapine was introduced. Unlike previous 
antipsychotic drugs, this particular drug was not only effective in reducing symptoms 
associated with schizophrenia, but carried with it a lower risk of inducing extrapyramidal 
symptoms.  As a result, clozapine was labeled as an “atypical” antipsychotic; as it disproved 
the assumption that extrapyramidal symptoms couldn’t be disentangled from the efficacy of 
the first generation antipsychotics.   In addition, clozapine showed an increase in efficacy 
for negative symptoms of schizophrenia, an increase in efficacy for treatment-refractory 
patients, as well as a lower likelihood of raising serum prolactin levels. (Shen, 1999) The 
actual pharmacological difference is that the primary mechanism for first generation 
antipsychotics is mediated through the dopamine D2 receptor blockade, whereas “atypical” 
antipsychotics (also known as second generation antipsychotics) use mixed dopamine 
receptors.  (Surja, Tamas, & El-Mallakh, 2006) The success of clozapine led to the 
development of several other similar antipsychotic drugs that include risperidone in 1994 
(marketed as Risperdal), olanzapine in 1996 (marketed as Zyprexa), quetiapine in 1997 
(marketed as Seroquel), ziprasidone in 2001 (marketed as Geodon), aripiprazole in 2002 




 The emergence of these “atypical” antipsychotics has had a tremendous influence in 
broadening the use of antipsychotic prescriptions, primarily through off-label use.  The 
reduction of extrapyramidal symptoms associated with these second generation 
antipsychotics has facilitated the expansion of their use for a wider variety of clinical 
indications and for a more diverse population including children and adolescents. Although 
off-label prescribing is common practice, it is a concern for antipsychotic prescribing, as this 
class of drugs still carries with it substantial risk.  Despite its perceived clinical advantage 
and safety, antipsychotic drug use has been associated with metabolic and developmental 
side-effects among children and adolescents.  Without substantial long-term safety data, 
the use of these drugs should be more closely monitored. (Crystal, Olfson, Huang, Pincus, & 
Gerhard, 2009)   
 
Pediatric Mental Health and Use of Antipsychotics 
  As the use of antipsychotics have broadened, use among children and adolescents 
has increased nearly two-fold over the past decade.  (America's State of Mind, 2011) 
Schizophrenia, bipolar disorder, attention deficit disorders, and autism have been the 
leading indications associated with the use of “atypical” antipsychotic prescriptions.  (Chai, 
Mehta, Moeny, & Governale, 2010) Changes in the identification of pediatric psychotic 
disorders and the expansion of use in non-psychotic disorders that include ADHD and 
autism have driven the uptake of these drugs among children and adolescents. (Ivanov & 
Charney, 2008) 
  The diagnostic criteria for disorders such as schizophrenia and bipolar disorder as 
defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM) are based on 




diagnosis for a child or adolescent.  Without a clear understanding of the psychopathology 
of these psychotic disorders, clinicians have been reluctant in the past to diagnose children 
and adolescents with these disorders, especially given the stigma and prognosis 
implications attached to them.  However, pediatric schizophrenia and bipolar disorder have 
become increasingly accepted diagnoses as more and more individuals are diagnosed with 
these conditions and retrospective studies provide validation and support.  Furthermore, 
the diagnostic criterion for these psychotic disorders has evolved with subsequent revisions 
of the DSM.  (Ivanov & Charney, 2008)  As the inclusion criterion has broadened and the 
diagnoses have become legitimized, a larger subset of the population has been captured 
with these disorders.  Over the last ten years, there has been a 40-fold increase in the 
diagnosis of bipolar disorder among children and adolescents.  (Moreno C. , Laje, Blanco, 
Olfson, Jiang, & Schmidt, 2007) 
 Psychotropic drug use has become increasingly common in managing autism 
spectrum disorders.  Otherwise referred to as ASD, autism spectrum disorders are a 
collection of neuro-developmental disorders that are characterized by social and 
communication deficits in addition to repetitive behavior.  It has been estimated that 
between 30-60% of children and adolescents with ASD use at least one psychotropic 
medication.  (Mandell, Morales, Marcus, Stahmer, Doshi, & Polsky, 2008)  Antipsychotics 
have become accepted practices to treat irritability, aggression, and self-injury associated 
with ASD.  Studies have found that haloperidol is effective in improving behavioral 
symptoms in children with autism.  However the high risk of extrapyramidal side effects 
has limited its use to only the most severe and treatment resistant cases.  Atypical 
antipsychotics are much more commonly used, given their reduced risk of extrapyramidal 




behavior associated with autistic disorders, despite lack of clinical efficacy data.  (Posey, 
Stigler, Erickson, & McDougle, 2008)  Although antipsychotic prescriptions such as 
risperidone have been proven to be effective in reducing these behavioral symptoms, it is 
unclear whether or not these drugs actually improve the social and communication 
impairments characteristic of autism.  Therefore it is necessary to consider the possibility 
that these drugs are simply mitigating side effects, as opposed to addressing the core 
problems.   
  Antipsychotics are also being prescribed to children and adolescents with ADHD, as 
they have been shown to be effective in reducing aggression.  A study looking at Medicaid 
enrollees in the state of Tennessee found that 46% of antipsychotics prescribed were for 
ADHD as a primary diagnosis.  (Cooper, Fuchs, Arbogast, & Ray, 2004)  In a national study 
by the Office of Surveillance and Epidemiology at the FDA found that in 2009, the third 
leading indication associated with the use of atypical antipsychotics among children and 
adolescents was for attention deficit disorders. (Chai et al., 2010) The increase in the 
percentage of antipsychotic prescribing for ADHD is a growing concern, as prescribing this 
class of drugs to treat non-psychotic conditions remains controversial.  Further 
complicating the trend in ADHD prescribing, is the high co-morbidity between ADHD and 
pediatric bipolar. Some physicians have questioned the safety and efficacy of stimulants in 
the treatment of children and adolescents with co-morbid ADHD/bipolar disorder.  There 
has been concern over whether or not long-term stimulant use induces mania and 
psychosis.  Given the complexity of differentiating between ADHD and bipolar, as well as 
the lack of substantial knowledge about the efficacy and safety of prescribing combinations 
of stimulants and antipsychotics (also referred to as poly-pharmacy), prescribing should be 





Adverse Effects Associated with Pediatric Antipsychotic Use 
  
 Despite their clinical effectiveness in treating schizophrenia and bipolar disorder, as 
well as managing aggression in non-psychotic disorders, antipsychotics still carry with 
them substantial risk of side effects.  Although atypical antipsychotics now represent the 
majority of antipsychotic prescriptions, these second generation antipsychotics are not risk 
free.  Children are more likely than adults to develop extrapyramidal side effects with 
risperidone and olanzapine.  In addition, children are at a higher risk of developing 
withdrawal dyskinesia associated with the discontinuation of an atypical antipsychotic 
drug.    (Ivanov & Charney, 2008) 
 Atypical antipsychotic use has also been associated in elevating levels of serum 
prolactin, which can develop into hyperprolactinemia.  Evidence suggests that this effect is 
most pronounced in adolescents.  Hyperprolactinemia can lead to hypogonadism (low 
estrogen in females and low testosterone in males), galatctorrhea, decreased libido, erectile 
dysfunction, osteoporosis, and possible delay in puberty. (Wudarsky, Nicolson, & 
Hamburger, 1999)  There is currently no research on the long-term effects of these 
impairments on cognitive and physical development.  
 The metabolic risk associated with atypical antipsychotic use has been the most 
concerning side effect.  In an eight-week trial, participants prescribed risperidone gained an 
average of 8 pounds, while participants prescribed olanzapine gained 13 pounds.  The 
tendency to promote excessive weight gain has become the focus of ongoing pediatric trials, 
as obesity poses serious health implications.  Weight gain for example is associated with 
elevated triglycerides and total cholesterol, as well as with metabolic syndrome and 
diabetes mellitus.  Metabolic syndrome is characterized with abdominal obesity, 




concern over metabolic effects was demonstrated when the FDA did not follow the Pediatric 
Advisory Committee’s controversial recommendation to approve Geodon (ziprasidone) in 
2009, as clinical trial data emerged revealing significant weight gain associated with 




 Differential prescribing patterns of antipsychotic drugs to children and adolescents 
raises concern over safety and access to proper mental health services.  According to an 
analysis of Medicaid and private insurance claims data, children and adolescents covered 
by Medicaid were four times more likely to receive an antipsychotic medication in 2004 
than those individuals with private insurance. ( (Crystal, Olfson, Huang, Pincus, & 
Gerhard, 2009) In addition there has been concern over higher rates of antipsychotic 
prescribing among foster kids.  A 2011 study found that foster kids were more likely to 
receive overlapping antipsychotic prescriptions and for longer durations than other kids 
enrolled in Medicaid.  In addition, black foster children were more likely than white 
children to be prescribed multiple antipsychotic drugs.  (dosReis, Yoon, Rubin, Riddle, Noll, 
& Rothbard, 2011)  Higher utilization among these vulnerable populations raises the 
question whether or not these children and adolescents are accurately being diagnosed and 
receiving the appropriate mental health care.  Most importantly, are these individuals 
being placed at a higher risk, as antipsychotics have become a cost-effective and short-term 
solution to mitigate larger systemic problems? 
 
FDA Regulatory Activity 
 In an effort to address insufficient pediatric data on dosing, safety, and efficacy, the 




505A of the US Food and Drug Administration Modernization Act, providing an additional 
6 months of patent protection or marketing exclusivity extension, in return for performing 
studies specified by the FDA.  The incentive program, also referred to as the Pediatric 
Exclusivity Provision was renewed in 2002 and in 2007 as part of the Best Pharmaceutical 
Children’s Act (BPCA).   In addition to using the “carrot” approach to encourage more 
pediatric trials, the 2003 Pediatric Research Equity Act granted the FDA the authority to 
require studies in children for a new drug likely to be used in pediatric populations.  As a 
result of these two approaches, the availability of pediatric data has substantially 
increased, leading to over 100 labeling changes.   (Vanchieri, Stith Buter, & Knutsen, 2008) 
 With the availability of more pediatric clinical trial data, the FDA approved the use 
of risperidone in children and adolescents ages 5-16 for the treatment of autistic disorder on 
October 6, 2006.  This was the first pediatric approval for an atypical antipsychotic.  Prior 
to this approval, only haloperidol and thioridazine (both first generation antipsychotics) 
were approved for children and adolescents.  The following is a timeline of the current 
pediatric approvals of atypical antipsychotics: 
 
Risperdal (risperidone) 
 October 6, 2006: Autistic disorder in children and adolescents ages 5-16 
 August 22, 2007:   Schizophrenia in adolescents ages 13-17 
    Short term treatment of manic or mixed episodes of bipolar  
    disorder in children and adolescents ages 10-17. 
 
Abilify (aripiprazole) 
 November 29, 2007 Schizophrenia in adolescents ages 13-17 
 February 27, 2008 Short term treatment of manic or mixed episodes of bipolar  
    disorder in children and adolescents ages 10-17. 
 November 19, 2009 Autistic disorder in children and adolescents ages 6-17 
  
Seroquel (quetiapine) 
 December 2009 Schizophrenia in adolescents ages 13-17 
    Short term treatment of manic or mixed episodes of bipolar  






 December 4 , 2009 :  Schizophrenia in adolescents ages 13-17 
    Short term treatment of manic or mixed episodes of bipolar  
    disorder in children and adolescents ages 10-17. 
 
  FDA regulatory activity on already approved drugs can have a profound as well as 
differential impact on the uptake and discontinuation of a drug.   (Gibbons, Brown, Hur, 
Bhaumik, Erkens, & Herings, 2007) (Olfson, Marcus, & Druss, 2008) (Busch & Barry, 2009)  
The FDA can positively impact utilization through new approvals and labeling changes, 
and negatively impact utilization through the use of black-box warnings and advisories.     
 The majority of research that has primarily concentrated on the effect of warnings 
and restrictions as opposed to approvals or labeling changes provides strong evidence for 
the influence of FDA regulatory activity.  The 2003 black-box warning on antidepressants 
regarding increased risk of suicidal behavior among pediatric patients resulted in a 
decrease in antidepressant use, demonstrating the influence of the FDA in conveying 
information.  In 2005, the FDA issued an advisory and a subsequent black-box warning on 
the risk of atypical antipsychotic use among elderly patients with dementia.  According to a 
study using office-based physician data, mentions of atypical antipsychotics fell 2% overall 
and 19% among those with dementia in the year following the advisories.  (Dorsey, 
Rabbani, Gallagher, Conti, & Alexander, 2010) The decrease in atypical antipsychotic drug 
use, especially among elderly dementia patients provide further support that FDA 
regulatory activity is closely watched and has a profound impact on drug prescribing 
trends.  Given the strong response to both the black-box warnings that were issued for 
pediatric antidepressant use and the warnings issued for elderly dementia patients, there is 






 Although there have been several reports on the trends in antipsychotic prescribing 
among children and adolescents, there have been no studies looking into how these trends 
have been affected by the pediatric FDA approvals that began in 2006.  Although drugs can 
be prescribed off-label, having an approval for a specific indication or population not only 
allows a drug to be marketed for a specific indication, but conveys a sense of safety by 
condoning and legitimizing its use.  Given the complexity of pediatric mental health 
disorders and the known safety risks associated with atypical antipsychotics, it is likely 
that physicians might be hesitant to prescribe off-label.  Therefore there it is hypothesized 
that these approvals have contributed to the increase in pediatric antipsychotic prescribing 
primarily among non-mental health specialists.  This study will examine these assumptions 




 To examine the effect of expanding FDA approvals to pediatric populations, this 
study focuses on the prescribing trends of Risperdal (risperidone) among children and 
adolescents ages 0-17 with respect to overall antipsychotic prescribing.  Using an 
interrupted time series design, this study looked at the individual and combined effect of 
the 2006 and 2007 FDA pediatric approval for the treatment of autism for individuals ages 
5-17, Schizophrenia for individuals ages 13-17, and bipolar disorder for individuals ages 10-
17.  A segmented regression analysis of interrupted time series data is the strongest, quasi-
experimental design, as it can examine the immediate and long-term effects of the FDA 





 Longitudinal data from IMS Health was used to look at antipsychotic prescribing 
from 2005 to 2008.  The data set includes retail pharmacy prescriptions data for a 
representative sample of children and adolescents ages 0-17 who filled an antipsychotic 
prescription during the time period.  This data set represents more than 60% of all annual 
retail prescriptions filled in the US.  Each prescription record contains a unique patient 
identifier, data about the patient (date of birth and sex), the name of the drug, the dose, the 
dispense date, the geographic location of where the prescription was written, a unique 
physician id number, and payment type (i.e. private insurance or cash).  This data set was 
merged using the unique physician id numbers with a data set containing demographic 
information on the providers that included specialty, age, and sex.   
 For the analysis, the raw data was collapsed to generate monthly counts of 
Risperdal as well as all antipsychotic prescriptions written by each physician to create the 
outcome variable.  Two indicator variables were created for two FDA approval dates, as 
well as two interaction terms between the interventions and time.  Month indicator 
variables were created to account for time effects and indicator variables for physician 
specialties were created to stratify the analysis.   
 
Model Specifications 
 To examine the changes in Risperdal prescribing with respect to the two FDA 
pediatric approvals in 2006 and in 2007, several segmented regression models were built 
analyzing provider-month counts of Risperdal. For the first set of analyses, each 
intervention was tested independently and then jointly.  Each of the segmented regression 




prescriptions written by each unique provider, offsetting for the total number of 
antipsychotics prescribed per month with robust standard errors clustered around unique 
physicians.  Although there was no evidence of over dispersion, the segmented regression 
models were also fitted using a negative binomial regression model as a robustness check.  
In addition, since Rispderal was so commonly prescribed among clinicians, there was no 
need to run a zero-inflated Poisson model. 
 
Model 1a:  
 log	 	 ∗ 	 ∗ 1 	 ∗ 	 	 1 	  
 
Model 2a: 
log	 	 ∗ 	 ∗ 2 	 ∗ 	 	 2 	  
 
Model 3a: 
log	 	 ∗ 	 ∗ 1 	 ∗ 	 	 1
∗ 2 	 ∗ 	 	 2 	 	  
 
Where: 
 For each of the regressions, the average provider-month counts of Risperdal 
prescriptions were modeled, offsetting for the average provider-month counts of total 
antipsychotic prescriptions 
 
  is measured in  t months beginning from January 2005 
 
  is an indicator variable where a value of 1 represents a prescription 
that was written after the first approval date (October 2006) 
 
 	 	  is an interaction between time measured in months and 
the first intervention dummy variable 
 
  is a dummy variable where a value of 1 represents a prescription 
that was written after the second approval date (November 2007) 
 
 	 	 is an interaction between time measured in months and 





 For the second set of analyses, 11 indicator variables to control for monthly time 
effects were added to the model.  April was chosen as the reference month since this month 
reflects average prescribing.   
 Finally, to examine the differential effects due to physician specialty, the combined 
models were analyzed by stratifying by pediatricians versus non-pediatricians and mental 
health specialists versus non-mental health specialists.   The mental health specialists 
consisted of psychiatrists, child psychiatrists, neurologists, and child neurologists.  These 
models were run with and without the month indicator variables. 
 To interpret the results of the interrupted time-series analyses, the pre- and post-
intervention slopes were plotted using the method of recycled predictions.  This process 
involved coding observations for each time period with a zero if they were before the 
intervention or a 1 if they occurred after the intervention.  (Liao, 1994)  STATA version 11.2 
was used to generate the predicated values as well as to run all of the statistical analyses.  
 
III. Results 
 In each of the regressions, there were 1,494,366 observations representing the 
monthly prescription counts of 140, 838 unique providers who wrote a least one 
antipsychotic prescription to a child or adolescent ages 0-17 from 2005-2008.  To highlight 
the breakdown by specialty, 18.53% specialized in Family Medicine, 17.78% in Pediatrics, 
14.66% in Psychiatry, and 7.51% in Internal Medicine. (Refer to Figure 1.2 and Table 1.3)  
These unique providers prescribed a combined total of 1, 025, 773 prescriptions for 
Risperdal in 2005, 1,245,078 in 2006, 1,337,050 in 2007, and 1,408,423 in 2008.  (Refer for 
Figure 1.1)  In addition, total antipsychotic prescribing volume was 2,335,727 in 2005, 




at total Risperdal prescribing by month, there appears to be seasonal trends, as evidenced 
by the dip in the number of Risperdal prescriptions written in March. (Refer to Figure 1.1) 
 Looking at the regressions modeling each of the interventions separately show a 
statistically significant effect of the FDA approvals on Risperdal prescribing.  The October 
2006 approval had a positive immediate effect on the level of Risperdal prescribing by 
shifting up the percent of Risperdal prescribing by 1.31% points (refer to figure 2.1b).  In 
addition, there was a positive effect on the trend of Risperdal prescribing as the post-
intervention slope increased.  The November 2007 approval also had an immediate effect on 
the level of Risperdal prescribing by shifting up the percent of Risperdal prescribing by 
1.04% points (refer to figure 2.2b).  However the effect on trend was negative, as the post-
intervention slope decreased. 
 Although modeling the effects of each approval separately provides useful insight 
into the short term effects of each approval, it is more accurate to model the approvals in a 
combined model, especially since there is less than a year between the two interventions. 
The results of the combined model show a positive effect on the level of Risperdal 
prescribing by shifting up the percent of Risperdal prescribing by 2.44% points (refer to 
figure 2.3b).  In addition, the slope following the two FDA approvals remained the same as 
the pre-intervention slope.  Therefore the overall long-term effect of the FDA approvals had 
a positive effect on the level of Risperdal prescribing, but did not have any effect on the rate 
at which Risperdal lost market share from 2005-2008.  In other words, the net effect of the 
approvals provided an additional 24.4 months of market share that would have otherwise 
would have naturally decayed due to loss of patent life, market competition, and loss of 
novelty. This estimate was calculated using the pre-intervention slope to solve for the 




 Stratifying the analyses by mental health specialists and non-mental health 
specialists suggest that the FDA approvals had a differential impact on physician 
prescribing by specialty.  As hypothesized, there was a greater effect on non-mental health 
specialists as the level of Risperdal prescribing shifted up 3.56% points versus 2.01% points 
among specialists (refer to Figures 4.1b and 4.2b).  In addition, stratifying the analysis by 
Pediatricians and non-Pediatricians found that the level of Risperdal prescribing shifted up 
by 4.02% points among Pediatricians versus 2.25% points among non-Pediatricians (Refer 
to Figures 3.1b and 3.2b).  Figure 5 in the appendix shows a comparison of these stratified 
regressions in terms of the number of months of market share gained as a result of the FDA 




 Although the FDA labeling change had a statistically significant impact on 
Risperdal prescribing trends, there are several factors that may have dampened the effects.  
First, there is substantial evidence to suggest that the trend in the uptake of antipsychotic 
drugs among children and adolescents began prior to the FDA labeling changes in 2006.  In 
the past decade, there have been several federal lawsuits against the leading antipsychotic 
drug manufacturers under the False Claims Act for deceptive practices as well as several 
state and individual class action law suits alleging off-label marketing.  In 2009, Pfizer paid 
$2.3 billion to settle allegations of illegally marketing Geodon, while Eli Lilly paid $1.4 
billion to settle lawsuits against Zyprexa.  In addition, Johnson and Johnson has paid $743 
million to settle lawsuits alleging fraud and illegal marketing practices to pediatric and 




have also been dampened by changes in the market for atypical antipsychotic drugs. During 
this period, Invega, a similar atypical antipsychotic was introduced.  In addition to 
competition from this new drug, pediatric approvals for Zyprexa (olanzapine), Seroquel 
(quetiapine), and Abilify (aripiprazole) may have also affected Risperdal prescribing trends.  
Alternatively, insurance coverage could have dampened the effect of FDA labeling changes.  
Use of two and three-tier cost structures to steer consumers and physicians to choose either 
lower cost or preferred drugs using price incentives may have impeded drug choice.  
However this is highly unlikely, as there were no generic alternatives available prior to 
2008.  
 Further interference in detecting the effect of the FDA labeling changes could be due 
to the fact that Risperdal went off patent in October, 2008.  Firms typically reduce their 
allocation of marketing expenditures to drugs that are approaching the end of their patent 
life.  Although Risperdal did gain pediatric approval, the new labeling change might not 
have been as heavily promoted since its patent was nearing expiration.  Therefore the 
market share of Risperdal was already in decline due to competition from newer and more 
heavily promoted drugs.  In addition, if resources were not allocated to detailing and DTCA, 
knowledge of the labeling changes to include pediatric populations would have been 
diffused more slowly through FDA press releases, popular media, journals, and word of 
mouth. 
 This study did not look at prescribing changes with respect to indication.  It would 
have been useful to look at whether the FDA approvals had differential effects based on 
indication.  This would have allowed us to see whether or not physicians were closely 
following FDA prescribing guidelines or merely interpreting the approvals as a broad 




to determine whether or not the FDA approvals have facilitated the off-label prescribing of 
antipsychotics for ADHD.   
 Lastly, this study focuses solely on Risperdal prescribing, rather than all 4 of the 
antipsychotics that were approved for pediatric use.  Looking the effects on these other 
antipsychotics could have provided further evidence to strengthen the Risperdal findings.  
In addition, this study focused on the effect of expanding antipsychotic labels.  Therefore 
the results of this study may not be applicable to other classes of drugs.  It is very likely 
that psychotropic drug prescribing patterns differ from other drug classes.   
 
Implications  
 The results of this study clearly suggest that FDA labeling changes to include 
pediatric populations had a significant impact on prescribing.  Prior to the pediatric FDA 
approval of Risperdal for autism, schizophrenia, bipolar disorder, all prescribing was off-
label.  Given the complexity and difficulties in diagnosing pediatric mood disorders as well 
as the risk of known and unknown adverse effects, it is reasonable to assume that 
physicians without specific mental health training as compared to psychiatrists might have 
been reluctant or less likely to prescribe antipsychotics to children and adolescents prior to 
the approvals.  The results of this study are consistent with this hypothesis and suggest 
that physicians, especially those without specific mental health training rely heavily on the 
FDA for guidance regarding safe and appropriate prescribing.  Therefore it is extremely 
important that pediatric approvals be made carefully, as they have the potential to have a 
strong influence on utilization and prescribing trends.      
 For the pharmaceutical industry, the results of this study provide compelling 




pediatric populations.  The combined effect of the Risperdal approvals for pediatric use 
resulted in shifting the market share of Risperdal prescribing by 2.44% points which is the 
equivalent to retaining 24.4 months of market share.  More broadly, the uptake in 
Risperdal in response to the FDA approvals in 2006 and 2007 reflects the influence of an 
approval conveying safety and legitimacy.   
 Although this study only examined the impact of the FDA approval of Risperdal for 
pediatric use, the increase in utilization and expenditure on antipsychotic drugs is most 
likely attributable in large part to these approvals.  Therefore future studies should focus 
on assessing the magnitude of the effect of FDA approvals on the increase in expenditures 
on antipsychotic drugs.  
 
Conclusion 
 Using retail prescription pharmacy data, an interrupted time-series analysis was 
used to look at the prescribing trends of Risperdal before and after the FDA approval for 
pediatric use in 2006 and 2006.   Given the results of this study that suggest FDA approvals 
have a significant effect on the level of prescribing but no significant effect on trend, it is 
extremely important to continue studying the effects of these approvals to determine 
whether this response has been harmful or beneficial.  Given the discrepancy in 
antipsychotic prescribing and the increasing off-label use for ADHD, there is suspicion to 
believe that FDA approvals may be broadly interpreted as legitimizing use among children 
and adolescents for all indications rather than for their specific approval.  This study 
provides the first assessment of the effect of the FDA approval of antipsychotic drugs for 
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Table 1: Descriptive Statistics 
 
 











Table 1.2 Physician Specialties 
 
Specialty Count Percent 
Family Medicine 26,098 18.53% 
Pediatrician 25,046 17.78% 
Psychiatrist 20,652 14.66% 
Internal Medicine 10,579 7.51% 
Nurse Practitioner 9,574 6.80% 
Family Practice 6,993 4.97% 
Child Psychiatrist 5,631 4.00% 
Physician Assistant 4,415 3.13% 
Emergency Room 4,163 2.96% 
      
Other 27,687 19.66% 
Total 140,838 100.00% 
  
Year Risperdal All 
Percent 
Risperdal 
2005  1,025,773  2,335,727  43.92% 
2006  1,245,078  2,910,539  42.78% 
2007  1,337,050  3,097,803  43.16% 





Individual and Combined Regression Models 
(Number of Observations foe each Regression= 1,494,366) 
Incidence Rate Ratios are reported in parentheses 
Asterisk denote statistical significance as follows: 
∗∗∗ . , ∗∗	. .05, ∗ 0.05 0.1  
  
  Model 1a Model 2a Model 3b Model 1b Model 2b Model 3b 
intercept (B0) 














































































































































































































jan (B6)   
0.0006263 
(1.0006)   
0.0112047*** 
(1.0113) 
feb (B7)   
0.0023173 
(1.0023)   
0.0070959*** 
(1.0071) 
mar (B8)   
-0.004673 
(.9953)   
0.0437541*** 
(1.0447) 
may (B9)   
-0.0017373 
(.9983)   
-0.004315*** 
(.9957) 
jun (B10)   
-0.009228*** 
(.9908)   
-0.015184*** 
(.9849) 
jul (B11)   
-0.011524*** 
(.9885)   
-0.021774*** 
(.9785) 
aug (B12)   
-0.0054505 
(.9946)   
-0.019240*** 
(.9809) 
sep (B13)   
-0.014428*** 
(.9857)   
-0.024247*** 
(.9760) 
oct (B14)   
-0.014348*** 
(.9858)   
-0.021297*** 
(.9789) 
nov (B15)   
-0.014325*** 
(.9858)   
-0.021647*** 
(.9786) 
dec (B16)   
-0.016638*** 




Incidence Rate Ratios are reported in parentheses 
Asterisk denote statistical significance as follows: 



































































jan (B6)   
0.011234*** 
(1.0113)   
.009524*** 
(1.0096) 
feb (B7)   
0.007004*** 
(1.0070)   
0.007379*** 
(1.0074) 
mar (B8)   
-0.043129*** 
(1.0441)   
0.022909*** 
(1.0232) 
may (B9)   
-0.005505*** 
(.9945)   
0.000531 
(1.0005) 
jun (B10)   
-0.016184*** 
(.9839)   
-0.009117*** 
(.9909) 
jul (B11)   
-0.023108*** 
(.9772)   
-0.013115*** 
(.9870) 
aug (B12)   
-0.020384*** 
(.9798)   
-0.008770*** 
(.9913) 
sep (B13)   
-0.023869*** 
(.9764)   
-021223*** 
(.9790) 
oct (B14)   
-0.020714*** 
(.9754)   
-0.021819*** 
(.9784) 
nov (B15)   
-0.0216923*** 
(9785)   
-0.018400*** 
(.9818) 
dec (B16)   
-0.026751*** 




Incidence Rate Ratios are reported in parentheses 
Asterisk denote statistical significance as follows: 








































































































Incidence Rate Ratios are reported in parentheses 
Asterisk denote statistical significance as follows: 





Figure 1 Descriptive Statistics 
 
 
(Figure 1.1 Count of Risperdal Prescribing by Month) 
 
 
The raw counts by month show an increase in the total number of Risperdal prescriptions 




(Figure 1.2 Percent Market Share by Month) 
 
 
There appears to be a decrease in the market share of Risperdal from 2005-2008. The cyclical 
pattern seems to suggest that there is a distinct season effect in Risperdal prescribing 


















































Individual and Combined Regression Models 
 
 
Figure 2.1a October 2006 Approval 
 
 
Difference at Month 23: 1.57% 
*Dashed line refers to the intervention (October 2006 FDA approval) 
 
 
Figure 2.1b October 2006 Approval with month dummies 
 
 
Difference at Month 23: 1.04% 

































Individual and Combined Regression Models 
 
 
Figure 2.2a November 2007 Approval 
 
 
Difference at Month 32: 1.31% 




Figure 2.2b November 2007 Approval with month dummies 
 
 
Difference at Month 32: 1.23% 



































Individual and Combined Regression Models 
 
 




Difference at Month 32: 3.20% 
*Dashed lines refer to the interventions (FDA approvals) 
 
 




Difference at Month 32: 2.44% 
































Pediatricians vs. Non-Pediatricians 
 




Difference at Month 32: 4.34% 
*Dashed lines refer to the interventions (FDA approvals) 
 
 




Difference at Month 32: 4.02% 



































Pediatricians vs. Non-Pediatricians 
  




Difference at Month 32: 3.06% 
*Dashed lines refer to the interventions (FDA approvals) 
 
 




Difference at Month 32: 2.25% 


































Mental Health Specialists  
 
(Figure 4.1a: Non-Mental Health Specialists) 
 
 
Difference at Month 32: 4.22% 
*Dashed lines refer to the interventions (FDA approvals) 
 
 
(Figure 4.1b: Non-Mental Health Specialists with month dummies) 
 
 
Difference at Month 32: 3.56% 

































Mental Health Specialists 
 
 (Figure 4.2a: Mental Health Specialists with month dummies) 
 
 
Difference at Month 32: 2.82% 
*Dashed lines refer to the interventions (FDA approvals) 
 
 
(Figure 4.2b: Mental Health Specialists with month dummies) 
 
 
Difference at Month 32: 2.01% 




































Figure 5: Effect of the Combined FDA Approvals 
 
 
 
